169 related articles for article (PubMed ID: 12941043)
1. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI.
Mutch NJ; Moore NR; Wang E; Booth NA
J Thromb Haemost; 2003 Sep; 1(9):2000-7. PubMed ID: 12941043
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
Guimarães AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
[TBL] [Abstract][Full Text] [Related]
3. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
[TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
5. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
6. Tissue-type plasminogen activator transgenic rats for evaluating inhibitors of the activated form of thrombin-activatable fibrinolysis inhibitor.
Ito Y; Noguchi K; Morishima Y; Yamaguchi K
Blood Coagul Fibrinolysis; 2018 Apr; 29(3):314-321. PubMed ID: 29538006
[TBL] [Abstract][Full Text] [Related]
7. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
[TBL] [Abstract][Full Text] [Related]
8. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
9. Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons.
Runge MS; Harker LA; Bode C; Ruef J; Kelly AB; Marzec UM; Allen E; Caban R; Shaw SY; Haber E; Hanson SR
Circulation; 1996 Sep; 94(6):1412-22. PubMed ID: 8823001
[TBL] [Abstract][Full Text] [Related]
10. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to arterial thrombolysis.
Klement P; Liao P; Bajzar L
Blood; 1999 Oct; 94(8):2735-43. PubMed ID: 10515877
[TBL] [Abstract][Full Text] [Related]
12. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
Schneider M; Nesheim M
J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
Kajimoto Y; Ohta T; Kuroiwa T
Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
[TBL] [Abstract][Full Text] [Related]
14. Pre-administration of a carboxypeptidase inhibitor enhances tPA-induced thrombolysis in mouse microthrombi: Evidence from intravital imaging analysis.
Mathews NS; Suzuki Y; Honkura N; Sano H; Iwashita T; Urano T
Thromb Res; 2022 Feb; 210():78-86. PubMed ID: 35030422
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
16. Microfluidic Modeling of Thrombolysis.
Loyau S; Ho-Tin-Noé B; Bourrienne MC; Boulaftali Y; Jandrot-Perrus M
Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2626-2637. PubMed ID: 30354249
[TBL] [Abstract][Full Text] [Related]
17. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
18. Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits.
Komissarov AA; Mazar AP; Koenig K; Kurdowska AK; Idell S
Am J Physiol Lung Cell Mol Physiol; 2009 Oct; 297(4):L568-77. PubMed ID: 19666776
[TBL] [Abstract][Full Text] [Related]
19. Remaining perspectives of mutant and chimeric plasminogen activators.
Lijnen HR; Collen D
Ann N Y Acad Sci; 1992 Dec; 667():357-64. PubMed ID: 1309056
[TBL] [Abstract][Full Text] [Related]
20. Bispecific monoclonal antibodies increase the fibrin-specific fibrinolytic activity of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA).
Bos R; Nieuwenhuizen W
Ann N Y Acad Sci; 1992 Dec; 667():428-30. PubMed ID: 1309066
[No Abstract] [Full Text] [Related]
[Next] [New Search]
